Oral Tranexamic Acid After Total Knee Arthroplasty

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Total Knee Arthroplasty

In brief

This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively. Hypothesis: Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.

Key facts

Study ID

NCT06894719

Run by

Rush University Medical Center

People needed

351

Starts

2026-09-01

Expected to finish

2027-05-01

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient undergoing primary TKA at Rush main hospital or participating ASC
• Willingness to undergo randomization to take medication potentially up to 7 days post op.
• Willing to answer daily questions on pain, functionality and opioid consumption

You may not qualify if…

• History of venous thromboembolism, MI, or stroke in the past year
• Patients on any chronic anticoagulation medications besides Aspirin
• Patients with Cancer
• Patients with end stage renal disease that are on dialysis
• Drug allergy to TXA
• Taking oral birth control
• Unable to provide consent

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.